Regulatory microRNAs-mediated cerebrovascular protection and traumatic braininjury

调节性 microRNA 介导的脑血管保护和创伤性脑损伤

基本信息

  • 批准号:
    10478480
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-10-01 至 2026-09-30
  • 项目状态:
    未结题

项目摘要

Traumatic brain injury (TBI) is a major medical concern in service personnel and veterans as currently no therapy is available to alleviate post-trauma neurological deficits. The blood-brain barrier (BBB) provides a dynamic interface to separate the brain from the circulatory system, maintaining a stable brain microenvironment. As a major component of the BBB, brain microvascular endothelial cells (BMECs), together with intercellular tight junctions (TJs), play a dominant role in modulating BBB integrity and paracellular permeability1. Accumulating evidence has demonstrated that BBB breakdown after TBI promotes a devastating cascade of events such as transmigration of peripheral immune cells, cerebral inflammatory responses, edema, and hemorrhagic transformation, contributing to secondary injury in neurotrauma. Thus, it is necessary to identify mechanisms and develop effective therapeutic strategies that protect BBB integrity and prevent permanent brain damage after TBI. MicroRNAs (miRs) function as a major class of small non-coding RNAs that negatively modulate protein expression. In addition to their critical role in various biological processes, miRs have also been implicated in a variety of human neurological diseases. We and others have shown the involvement of miRs in the pathogenesis of TBI. However, the functional significance and molecular mechanisms of miR molecules in regulating cerebrovascular pathogenesis, in particular BBB disruption/dysfunction, and resultant long-term neurological outcomes are poorly understood in TBI. The miR-15a/16-1 cluster is the first identified miR group associated with human carcinogenesis. Dysregulated plasma miR-15a/16-1 levels have been found in TBI individuals, showing great potential as useful biomarkers in clinical diagnosis and prognosis. Interestingly, molecular inhibition of miR-15a/16-1 levels has been shown to protect against myocardial infarction (MI) and ischemic brain injury. Therefore, American and European pharmaceutical companies consider the miR-15a/16-1 cluster as one of the most important miR targets to develop miR-based drugs for the treatment of MI. In our recent preliminary studies, we have shown that expression of the miR-15a/16-1 cluster is selectively increased in the mouse cerebral vasculature after TBI. Of note, endothelial cell (EC)-selective miR- 15a/16-1 genetic deficiency leads to reduced BBB leakage, and less neuronal loss, white matter (WM) injury, and neurobehavioral impairments in mice after TBI. We also found that the miR-15a/16-1 cluster can bind to the 3’-UTRs of major BBB tight junctions, brain-enriched Claudins, and inhibit their translation, and genetic silencing or deletion of the miR-15a/16-1 cluster significantly increased endothelial or cerebral expression of claudins. These findings have provided the basis for our Central Hypothesis that genetic deletion of vascular miR-15a/16-1 attenuates BBB disruption and subsequent pathological cascades after TBI, thereby contributing to increased BBB stabilization, reduced neuronal/WM loss, and improved long- term neurological outcomes in TBI. Three aims will be performed in this proposal. Aim 1: Define the role of vascular miR-15a/16-1 in post-traumatic BBB dysfunction and TBI outcomes; Aim 2: Elucidate the mechanisms of miR-15a/16-1 regulation of post-traumatic BBB dysfunction; Aim 3: Explore systematic delivery of miR- 15a/16-1 antagomir (inhibitor) as a potential therapy in TBI through BBB stabilization. Elucidating the molecular mechanisms of miR-15a/16-1-mediated BBB dysfunction may lead us to discover novel and effective treatment against TBI.
创伤性脑损伤(TBI)是现役军人和退伍军人的主要医疗问题

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kejie Yin其他文献

Kejie Yin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kejie Yin', 18)}}的其他基金

Targeting Kruppel-like Transcription Factor for White and Grey Matter Protection in Vascular Cognitive Impairment and Dementia
针对血管认知障碍和痴呆症中白质和灰质保护的 Kruppel 样转录因子
  • 批准号:
    10625096
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Role of nitro-fatty acids in BBB stabilization and post-stroke neurovascular protection
硝基脂肪酸在血脑屏障稳定和中风后神经血管保护中的作用
  • 批准号:
    10293575
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Role of nitro-fatty acids in BBB stabilization and post-stroke neurovascular protection
硝基脂肪酸在血脑屏障稳定和中风后神经血管保护中的作用
  • 批准号:
    10007200
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Role of nitro-fatty acids in BBB stabilization and post-stroke neurovascular protection
硝基脂肪酸在血脑屏障稳定和中风后神经血管保护中的作用
  • 批准号:
    10514600
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Kruppel-like factor 11 and ischemic stroke
Kruppel 样因子 11 与缺血性中风
  • 批准号:
    8963735
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Kruppel-like factor 11 and ischemic stroke
Kruppel 样因子 11 与缺血性中风
  • 批准号:
    9178989
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Kruppel-like factor 11 and ischemic stroke
Kruppel 样因子 11 与缺血性中风
  • 批准号:
    9063097
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Kruppel-like factor 11 and ischemic stroke
Kruppel 样因子 11 与缺血性中风
  • 批准号:
    9243321
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了